ANI Pharmaceuticals Inc

ANIP

Company Profile

  • Business description

    ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

  • Contact

    210 Main Street West
    BaudetteMN56623
    USA

    T: +1 218 634-3500

    E: [email protected]

    https://www.anipharmaceuticals.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    897

Stocks News & Analysis

stocks

Weekly Earnings Wrap: CBA, CSL, MQG and more

Everything you need to know on last weeks earnings results
stocks

ASX player rallies on small guidance upgrade

Our fair value is maintained despite investor enthusiasm.
stocks

After earnings, is Alphabet stock a buy, a sell, or fairly valued?

With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,138.8066.60-0.72%
CAC 408,304.159.09-0.11%
DAX 4024,895.6442.950.17%
Dow JONES (US)49,525.2573.270.15%
FTSE 10010,441.6439.200.38%
HKSE26,567.12465.42-1.72%
NASDAQ22,592.654.50-0.02%
Nikkei 22556,941.97697.87-1.21%
NZX 50 Index13,198.18309.10-2.29%
S&P 5006,846.6613.900.20%
S&P/ASX 2008,917.6055.30-0.62%
SSE Composite Index4,082.0751.95-1.26%

Market Movers